Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Breast Cancer
Phase NA
Enrollment 25
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The diagnosis of breast cancer and the treatments implemented have a significant impact on the professional situation. Maintaining employment and/or reintegration into working life are therefore major issues for cancer patients. This trial proposes to study the feasibility of a support/coaching program for a return to work in patients after breast cancer.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Other: Questionnaires — Quality of life questionnaires, work perception questionnaires, psychological distress questionnaire
  • Other: back to work coaching — Back-to-work support program including an individual interview to identify patient needs and expectations, 7 coaching workshops (every 3 weeks +/- 15 days) and a final individual assessment post workshops

Primary Outcomes

  • Patient adherence of a coaching program for an adapted return to work (through study completion, an average of 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-09-13
Completion: 2027-08-22
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 25 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle
Principal Investigators:
  • Estelle Guerdoux, Dr (STUDY_CHAIR) - Institut du Cancer de Montpellier - Val d'Aurelle
Contact Information
Study Contact:
Jean-Pierre Bleuse
04 67 61 31 02
jean-pierre.bleuse@icm.unicancer.fr
Estelle Guerdoux, Dr
04 67 61 24 68
estelle.guerdoux-ninot@icm.unicancer.fr
Institut du Cancer de Montpellier
Interventions
  • Other: Questionnaires — Quality of life questionnaires, work perception questionnaires, psychological distress questionnaire
  • Other: back to work coaching — Back-to-work support program including an individual interview to identify patient needs and expectations, 7 coaching workshops (every 3 weeks +/- 15 days) and a final individual assessment post workshops
Study Locations (1 sites)
Institut du Cancer de Montpellier, Montpellier, 34298 France
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years * Patients cared at the Montpellier Cancer Institute (ICM) for non-metastatic breast cancer who have received adjuvant treatment (radiotherapy and/or chemotherapy) * Patient who has completed adjuvant treatment, except for hormonotherapy * Patient practicing a profession at the time of diagnosis, looking for a job or in professional retraining at the time of diagnosis * Patient expressing spontaneously or on request of the oncologist physical or psychological difficulties in the professional field * Patient wishing to be accompanied for an adapted return to her current job or for a return to a new more adapted job * Patient who signed the informed consent after informed information by her clinician Exclusion Criteria: * Metastatic breast cancer or any other cancer within the last 5 years * Patient who haven't completed herr adjuvant treatment (chemotherapy and/or radiotherapy) * Psychological condition requiring therapeutic support (objectified by the Mini International Neuropsychiatric Interview test (MINI) by identifying a Diagnostic and Statistical Manual (DSM)-IV Axis I psychiatric disorder (American Psychiatric Association, 1994) Sheehan et al., 1998) with the patient's refusal of adequate psychiatric treatment (medicated or not) at the time of inclusion in the study * Severely impaired global cognitive functioning (objectified by an adjusted score of less than 20 on the Montreal Cognitive Assessment (MoCA) test) * Physical inability to answer questionnaires
Conditions Anxiety Disorders and Symptoms, Fibromya...
Phase Not Applicable
Enrollment 25
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Herbal Medicine is known as the medicinal use of herbal substances as a means of treating different conditions in the human body to ensure that the body remains in optimal health and wellness. These substances are known to contain very active ingredients in it and as such is also a very potent means of managing diseases and ailments in the body. Herbal medicine has always been a standby source of getting relief from various conditions over centuries, however, it can be categorically said that the mode of usage of these herbal substances has changed over time. Traditional healers help individuals to make meaning out of the natural herbs seen around that can be useful to one's health. Herbal medicine is the use of plants to treat disease and enhance general health and wellbeing. Herbs can interact with other pharmaceutical medications and should be taken with care. Always seek a regular medical doctor (GP) about any health concerns and tell them about any herbal medicines you are taking or thinking of taking. Never stop taking prescribed medications in favor of herbs without first discussing it with your GP.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Dietary Supplement: IV Vitamin Infused Therapy Treatment — Vitamin B, C, D, E, K, liquid vitamins, antioxidants, amino acids, and minerals
  • Drug: Herbal medicine — Herbal medicine is the use of plants to treat disease and enhance general health and wellbeing. Examples of common herbal health products and supplements include black cohosh, echinacea, garlic, ginkgo, saw palmetto, and St. John's wort just to name a few.

Primary Outcomes

  • Reduction in Symptoms related to Specific Illness or Disorder (8-12 weeks, varying with each Intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-12-21
Completion: 2026-09-17
Eligibility
Age: 21 Years and older
Sex: ALL
Volunteers: true
Enrollment: 25 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Faith A. Richardson
Contact Information
Study Contact:
Faith A Richardson, BSW, MPA, CBT, DBT, PhD
302-363-3773
healthforlifewellnesscenterllc@gmail.com
Health for Life Holistic Wellness Center LLC
Faith A Richardson, BSW, MPA, CBT, DBT, PhD
Health for Life Holistic Wellness Center LLC
Interventions
  • Dietary Supplement: IV Vitamin Infused Therapy Treatment — Vitamin B, C, D, E, K, liquid vitamins, antioxidants, amino acids, and minerals
  • Drug: Herbal medicine — Herbal medicine is the use of plants to treat disease and enhance general health and wellbeing. Examples of common herbal health products and supplements include black cohosh, echinacea, garlic, ginkgo, saw palmetto, and St. John's wort just to name a few.
Study Locations (1 sites)
Health for Life Holistic Wellness Center LLC, Dover, Delaware 19901 United States
Eligibility Criteria
Inclusion Criteria: * N/A Exclusion Criteria: * N/A
Conditions Solid Tumor, Adult, Colorectal Cancer, N...
Phase Not Applicable
Enrollment 500
Locations 16 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for future use to make CAR T-Cell therapy for their disease treatment. Design: This is a non-interventional, observational study to evaluate participants with solid tumors with a high risk of relapse for incurable disease. No interventional therapy will be administered on this study. Some of the information regarding the participant's tumor analysis may be beneficial to management of their disease. Participants that meet all criteria may be enrolled and leukapheresed (blood cells collected). The participant's cells will be processed and stored for potential manufacture of CAR T-cell therapy upon relapse of their cancer.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Apheresis — Apheresis procedure performed for collection of PBMCs.
  • Diagnostic Test: Next Generation Sequencing (NGS) — NGS on tumor tissue and a matched normal sample for loss of heterozygosity in tumor tissue and tumor tissue markers.
  • Diagnostic Test: Long Range NGS HLA typing — Long range NGS on whole blood to determine germline HLA type.

Primary Outcomes

  • Percentage of participants who can enroll in an A2 Biotherapeutics, Inc. CAR T-cell therapy study after undergoing apheresis (up to 2 years)
  • Percentage of screened participants experiencing loss of heterozygosity (LOH) of HLA-A*02 identified by next generation sequencing (Screening)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2021-10-29
Completion: 2029-04
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: A2 Biotherapeutics Inc.
Collaborators: Tempus AI
Principal Investigators:
  • Eric W Ng, MD, FAAP (STUDY_DIRECTOR) - A2 Biotherapeutics Inc.
Contact Information
Study Contact:
Clinical Trials
(310)431-9180
ClinicalTrials@a2bio.com
Jace Luzania
480-256-5483
Jace.Luzania@bannerhealth.com
Banner Health
Matthew Ulrickson, MD
Banner Health
Interventions
  • Other: Apheresis — Apheresis procedure performed for collection of PBMCs.
  • Diagnostic Test: Next Generation Sequencing (NGS) — NGS on tumor tissue and a matched normal sample for loss of heterozygosity in tumor tissue and tumor tissue markers.
  • Diagnostic Test: Long Range NGS HLA typing — Long range NGS on whole blood to determine germline HLA type.
Study Locations (16 sites)
Banner Health, Gilbert, Arizona 85234 United States
Mayo Clinic Hospital, Phoenix, Arizona 85054 United States
City of Hope, Duarte, California 90101 United States
University of California San Diego, La Jolla, California 92093 United States
Stanford University, Palo Alto, California 94304 United States
UCLA Medical Center, Santa Monica, California 90404 United States
Mayo Clinic Jacksonville, Jacksonville, Florida 32224 United States
Moffitt Cancer Center, Tampa, Florida 33136 United States
Massachusetts General Hospital/Dana Farber Cancer Institute, Boston, Massachusetts 02114 United States
Mayo Clinic Rochester, Rochester, Minnesota 55905 United States
Eligibility Criteria
Key Eligibility Criteria (additional criteria may apply) Part 1 Key Inclusion Criteria 1\. Pathologically confirmed solid tumors, e.g., Colorectal Cancer (CRC), Non-Small Cell Lung Cancer (NSCLC), or Pancreatic Cancer (PANC), that is metastatic, unresectable locally advanced, or in the Investigator's opinion the subject is high risk for incurable relapse within two years. Part 1: Key Exclusion Criteria 1. History of any of other malignancy in the past 5 years other than non-melanoma skin carcinoma, low grade localized prostate cancer, superficial bladder cancer, ductal carcinoma in situ (CIS) of the breast, CIS of the Cervix, or Stage I uterine cancer. 2. Prior allogeneic stem cell transplant. 3. Prior solid organ transplant. Part 2 : Key Inclusion Criteria 1. Pathologically confirmed solid tumors, e.g., Colorectal Cancer (CRC), Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer (PANC), Mesothelioma, or Ovarian Cancer (OVAC) that is metastatic, unresectable locally advanced, or in the Investigator's opinion the subject is high risk for incurable relapse within two years. 2. Participants are germline HLA-A\*02 heterozygous confirmed by HLA typing. 3. Primary tumor tissue showing LOH of HLA-A\*02 by NGS testing. 4. Eastern Cooperative Oncology Group (ECOG) 0 or 1 performance status. Part 2: Key Exclusion Criteria 1. History of any of other malignancy in the past 5 years other than non-melanoma skin carcinoma, low grade localized prostate cancer, superficial bladder cancer, ductal carcinoma in situ (CIS) of the breast, CIS of the Cervix, or Stage I uterine cancer. 2. Prior allogeneic stem cell transplant. 3. Prior solid organ transplant. 4. Participants who have received any cancer therapy on any investigational therapy for any indication, including but not limited to chemotherapy, small molecules, monoclonal antibodies, or radiotherapy (with bone marrow impact) within 2 weeks of planned apheresis or 3 half-lives, whichever is shorter. 5. Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment necessitating specific treatment, or any major episode of infection requiring treatment with Intravenous (IV) antimicrobials (e.g., IV antibiotics) or hospitalization (relating to completion of antibiotic course). 6. Has known active central nervous system metastases. Subjects with previously treated brain metastases may participate upon medical monitor agreement. 7. In the Investigator's judgement, any other condition or reason the subject would not complete the required study visits and procedures, and follow up visits, or comply with the study requirements for participation.

Scalp Cooling in MBC

NCT04986579
Recruiting
Conditions Metastatic Breast Cancer, Chemotherapy-i...
Phase PHASE2
Enrollment 120
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This research is being done to compare rates of hair loss of people with metastatic breast who use scalp cooling versus those who do not use scalp cooling after receiving standard of care treatment with either sacituzumab govitecan, trastuzumab deruxtecan, or eribulin. The name of the study intervention involved in this study is: * Paxman Scalp Cooling System

Design

Study type: Interventional Phases: Phase2 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Device: Paxman Scalp Cooling System — Cap attached to coolant lines connected to a refrigeration unit placed on scalp
  • Drug: Eribulin — Intravenous Infusion
  • Drug: Sacituzumab govitecan — Intravenous Infusion
  • Drug: Trastuzumab deruxtecan — Intravenous Infusion

Primary Outcomes

  • Hair Loss Rate (Up to 2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2021-10-07
Completion: 2030-06-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Dana-Farber Cancer Institute
Collaborators: Paxman Coolers Limited, AstraZeneca, Eisai Inc., Daiichi Sankyo, Gilead Sciences
Principal Investigators:
  • Elahe Salehi, DNP, ANP-BC (PRINCIPAL_INVESTIGATOR) - Dana-Farber Cancer Institute
Contact Information
Study Contact:
Elahe Salehi, DNP, ANP-BC
617-632-3800
elahe_salehi@dfci.harvard.edu
Elahe Salehi, DNP, ANP-BC
617-632-3800
elahe_salehi@dfci.harvard.edu
Brigham and Women's Hospital
Elahe Salehi, DNP, ANP-BC
Brigham and Women's Hospital
Interventions
  • Device: Paxman Scalp Cooling System — Cap attached to coolant lines connected to a refrigeration unit placed on scalp
  • Drug: Eribulin — Intravenous Infusion
  • Drug: Sacituzumab govitecan — Intravenous Infusion
  • Drug: Trastuzumab deruxtecan — Intravenous Infusion
Study Locations (2 sites)
Brigham and Women's Hospital, Boston, Massachusetts 02115 United States
Dana Farber Cancer Institute, Boston, Massachusetts 02115 United States
Eligibility Criteria
Inclusion Criteria: * Men and women with a diagnosis of metastatic invasive breast cancer with a ECOG PS≤2 * Participant is ≥ 18 years old. * Hair present at baseline. * One of the following full dose chemotherapy regimens must be planned for at least 4 cycles: * Sacituzumab govitecan (IMMU-132) 10 mg/kg administered intravenously on days 1 and 8 of each 21-day cycle * Trastuzumab deruxtecan 5.4 mg/kg administered intravenously once every 3 weeks * Eribulin 1.4 mg/m2 administered intravenously on days 1 and 8 of each 21-day cycle * The Paxman Scalp Cooling System must be initiated with the first dose of therapy in participants that elect to participate in the scalp cooling group. Exclusion Criteria: * Known hematological malignancies (i.e. leukemia or lymphoma) * Known scalp metastases. * Baseline alopecia (defined CTCAE 5.0 grade \> 0, see Appendix B) * Subjects with cold agglutinin disease or cold urticaria. * Subjects who are scheduled for bone marrow ablation chemotherapy. * Personal history of migraines, cluster or tension headaches as defined as actual medical diagnosis by a physician and/ or prescribed medications. If personal history of migraines was related to a past medical problem that is now resolved, the subject may go on study at the discretion of the Principal Investigator. * Subjects who have lichen planus or lupus. * Participants who are receiving any additional anti-cancer agents
Conditions Pre-diabetes
Phase EARLY_PHASE1
Enrollment 66
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Newly released guidelines recommend increased physical activity (PA) and reduced sedentary behaviors (SB) to improve glycemia and prevent the onset and progression of type 2 diabetes (T2D). Typically, 30-60 min bouts of PA are advocated per day. Although this approach increases PA, it does not decrease the length of the sedentary periods through the day. This is important because recent epidemiological data suggest that frequently interrupting sedentary time improves glucose control even in people who achieve the recommended levels of PA. Preliminary experimental data suggest that breaking up prolonged sedentary time by performing multiple short bouts (5 min) of PA throughout the day, may improve glycemia more than performing a single continuous bout of PA, and thereby potentially be a novel strategy to prevent T2D. The improvement in glycemia was observed even when the total amount of PA and total energy expenditure were matched, suggesting that how and when PA is performed over the day may matter more than how much PA is done. However, important gaps in knowledge remain including: (1) whether similar benefits on glucose control would be observed in adults with prediabetes, a clinically relevant population that is at high risk of developing T2D; (2) whether these effects are sustained or diluted over time, and (3) what are the mechanistic underpinnings. To address these gaps, the investigators propose to measure the acute and chronic effects of PA breaks on glucose control and the underlying mechanisms in individuals at risk of developing T2D. Sedentary men and women with prediabetes (n=66, 50% F) will be randomized to either an intervention designed to interrupt SB with 5-min bouts of brisk walking performed hourly for 9 hours/day, 5 days/week (BREAK) or a control condition consisting of 45-min of brisk walking performed as a single daily continuous bout, 5 days/week (ONE). The two 3-months interventions will be matched for total active time.

Design

Study type: Interventional Phases: Early Phase1 Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Behavioral: BREAK — The BREAK intervention is a physical activity regimen.
  • Behavioral: ONE — The ONE intervention is a physical activity regimen.

Primary Outcomes

  • Glycemia (Glucose concentration in mg/dl, measured at fasting, during a 2 hour OGTT and after)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: Recruiting
Start Date: 2021-11-30
Completion: 2026-11-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 66 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Colorado, Denver
Principal Investigators:
  • Audrey Bergouignan, PhD (PRINCIPAL_INVESTIGATOR) - University of Colorado, Denver
Contact Information
Study Contact:
Patricia Smith, MS, RDN
303.724.6821
trish.smith@cuanschutz.edu
Audrey Bergouignan, PhD
303.724.9026
audrey.bergouignan@cuanschutz.edu
Audrey Bergouignan, PhD
University of Colorado Anschutz Medical Campus
Interventions
  • Behavioral: BREAK — The BREAK intervention is a physical activity regimen.
  • Behavioral: ONE — The ONE intervention is a physical activity regimen.
Study Locations (1 sites)
University of Colorado Anschutz Medical Campus, Aurora, Colorado 80045 United States
Eligibility Criteria
Inclusion Criteria: * Male and female * BMI of 18.5-40 kg/m2 and weight stable over the previous 6 months. * Age, 18-64 years old. * Fasting glucose of 100-125 mg/dL or fasting HbA1c of 5.7-6.4%, or 2h OGTT blood glucose of 140-199mg/dL based on the American Diabetes Association criteria for pre-diabetes. Fasting glucose, HbA1c and OGTT results ordered by the participant's provider within 3-months of the screening visit will be accepted, provided they fall within the measurement of error range established by the institution's lab standards. Additionally, consistent use of Metformin (1 year) to prevent prediabetes from developing diabetes will be accepted. * Less than 150 minutes of moderate-to-vigorous physical activity (MVPA) per week and more than 6 hours of sitting time per day, as self-reported by the volunteers using the International Physical Activity Questionnaire (IPAQ). * Less than 6500 of steps per day as measured by a pedometer over 5 days (at least 1 weekend day). * Passing medical and physical screening, and analysis of blood and urine screening samples. * Low-moderate caffeine use (\<3 cups/day). * Agree to refrain from any other structured exercise than the physical activity prescribed in each arm of the study. * Agree to eat control diets for 3 days before and during the Clinical and Translational Research Center (CTRC) visits; * Agree to refrain from taking any over-the-counter (including nonsteroidal anti-inflammatory drugs) or prescribed medication (apart from oral contraceptives) for 3 days prior to the inpatient CTRC visits; * Agree to wear a Fitbit® activity monitor and upload data on the website on a daily basis for the whole duration of the study. * Agree to follow the physical activity interventions and to be randomly assigned to one of the two arms of the study. * Agree to complete all the study procedures. Exclusion Criteria: * Pregnancy, breast-feeding or post-menopause for women. * Being considered unsafe to participate as determined by the study physician. * Ever having a history of systemic, psychiatric, neurological disease, or drug and alcohol abuse. * History of cardiovascular disease, diabetes, uncontrolled hypertension, untreated thyroid, renal, hepatic diseases, dyslipidemia or any other medical condition affecting weight or lipid metabolism. * Being positive for human immunodeficiency virus or hepatitis B or C. * Taking medications affecting weight, triglycerides, energy intake/energy expenditure, or sleep in the last 3 months. * Having abnormal blood chemistry and/or hematology as deemed significant by the study physician. * Being a smoker or having been a smoker in the 3 months prior to their screening visit. * Having donated over 400 mL of blood within 3 months (90 days) of screening for the study; * Working night shifts within 1 month of and throughout the study. * Not completing the trial days of BREAK and ONE during the screening period to assess the willingness and ability of the participant to perform each of the interventions.
Conditions Depressive Disorder, Major
Phase NA
Enrollment 122
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The aim is to evaluate aerobic group exercise versus leisure group activities in adolescents with mild to moderate depression. Primary outcome is Children's Depression Rating Scale - Revised (CDRS-R). Secondary outcomes are Clinical Global Impressions - Severity and Improvement scales (CGI), self-reported Quick Inventory of Depression Symptomatology (QIDS- A17-SR), the self-reported Outcome Rating Scale (ORS), clinician rated Children Global Assessment Scale (C-GAS), aerobic capacity (VO2max), muscular strength, body, Body Mass Index (BMI), presence or activity of selected biological markers of neuroprotection and neuroinflammation in blood samples and a cost evaluation rated by parents with Trimbos/iMTA questionnaire for Costs associated with Psychiatric Illness - Child version (Tic-P) and the Child Health Utility (CHU9D) to facilitate estimation of Quality Adjusted Life Years. Further objectives are qualitative interviews to explore adolescents' experiences of the intervention as well as how their health and lifestyle are influenced and a validation of QIDS- A17-C and QIDS- A17-SR versus CDRS-R will be performed.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Aerobic exercise in group — The goal with every new week should be making every workout a little bit harder than the week before. Strength sessions Week 1- 6: 12-18 repetitions (reps) x 2 set per exercise and muscle 30 seconds (s) rest between exercise Week 7-12: 10-12 reps x 3 set per exercise and muscle 20 s rest between exercises Adding weight with gym equipment or changing body position in the exercises to succeed with the rep scheme and making it harder as the group develop their physical and mental ability. Conditioning sessions Week 1- 6: 75 seconds work time x 1 set per exercise 30 seconds of rest between exercises Week 7-12: 50 seconds work time x 2 set per exercise 20 seconds of rest between exercises Mixed sessions Week 1- 6: 35 s work time per exercise 25 s rest between exercises x 2 rounds Week 7-12: 45 s work time per exercise 15 s rest between exercises x 2 rounds
  • Behavioral: Leisure activities in group — The control group will receive leisure activity in a group setting for one hour three times a week for 12 weeks. The sessions will be held at the same weekdays and about the same hours as the exercise group sessions. The same group leaders as in the exercise sessions will participate in leisure sessions and will support the adolescents through reminders and reassurance before and during the sessions to enhance adherence. The sessions will start with a check in on feelings, recent events and difficulties (i.e. supportive listening but not any interventions) followed by non heart rate increasing activities, such as playing games or cards together

Primary Outcomes

  • Change in Children's Depression Rating Scale- Revised (CDRS-R) (After intervention (at 13 weeks = primary endpoint) but also at 26 weeks (still blinded)and at follow-up (at 52 weeks, non-blinded))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-02-28
Completion: 2026-03-10
Eligibility
Age: 13 Years and older
Sex: ALL
Volunteers: false
Enrollment: 122 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Lund University Hospital
Collaborators: Region Halland, Halmstad University, Karolinska University Hospital, The Rydberg Laboratory for Applied Sciences, Halmstad, Sweden, Region Skane, PRIMA Barn- och Vuxenpsykiatri AB
Contact Information
Study Contact:
Håkan Jarbin, MD, PhD
+46706778006
hakan.jarbin@regionhalland.se
Rebecca Mortazavi, MD
+46738011091
rebecca.mortazavi@regionhalland.se
Håkan Jarbin, MD PhD
+64226961628
hakan.jarbin@regionhalland.se
Region Halland
Interventions
  • Behavioral: Aerobic exercise in group — The goal with every new week should be making every workout a little bit harder than the week before. Strength sessions Week 1- 6: 12-18 repetitions (reps) x 2 set per exercise and muscle 30 seconds (s) rest between exercise Week 7-12: 10-12 reps x 3 set per exercise and muscle 20 s rest between exercises Adding weight with gym equipment or changing body position in the exercises to succeed with the rep scheme and making it harder as the group develop their physical and mental ability. Conditioning sessions Week 1- 6: 75 seconds work time x 1 set per exercise 30 seconds of rest between exercises Week 7-12: 50 seconds work time x 2 set per exercise 20 seconds of rest between exercises Mixed sessions Week 1- 6: 35 s work time per exercise 25 s rest between exercises x 2 rounds Week 7-12: 45 s work time per exercise 15 s rest between exercises x 2 rounds
  • Behavioral: Leisure activities in group — The control group will receive leisure activity in a group setting for one hour three times a week for 12 weeks. The sessions will be held at the same weekdays and about the same hours as the exercise group sessions. The same group leaders as in the exercise sessions will participate in leisure sessions and will support the adolescents through reminders and reassurance before and during the sessions to enhance adherence. The sessions will start with a check in on feelings, recent events and difficulties (i.e. supportive listening but not any interventions) followed by non heart rate increasing activities, such as playing games or cards together
Study Locations (4 sites)
Region Halland, Halmstad, 30290 Sweden
Prima Barn och vuxenpsykiatri AB (Stockholm-Handen), Stockholm, 11846 Sweden
PRIMA Barn och vuxenpsykiatri AB (Stockholm-Järva), Stockholm, 11846 Sweden
Region Halland, Varberg, 43343 Sweden
Eligibility Criteria
Inclusion Criteria: * DSM-5 mild to moderate depression * who have received evaluation and basic psychosocial interventions for 4-8 weeks (minimum three visits) without response, i.e. not achieved improvement by at least 50 % as assessed from clinical records Exclusion Criteria: * Severe depression * Eating disorder * High risk for suicide * Intellectual disability * Actual physical activity the last four weeks meeting the level for sustained health by American College of Sports Medicine, i.e. at least 150 min per week of moderate intensity or 75 min per week of high intensity38 * Adjustment of antidepressant medication within the last four weeks or stimulants the last two weeks * Chronic somatic illness precluding exercise * In need of interpreter * Social circumstances interfering with a regular exercise schedule * Concomitant psychotherapy
Conditions Triple-negative Breast Cancer
Phase PHASE2
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a Phase II, open-label, seven-arm parallel study evaluating the efficacy and safety of combined treatment (sodium cromoglicate, choline, efavirenz, SHR 1811, SHR 2102, mecapegfilgrastim, theophylline) with immune checkpoint inhibitor or immune checkpoint inhibitor rechallenge(AK131) in mTNBC (triple negative breast cancer) patients who progressed during previous immune checkpoint inhibitors.

Design

Study type: Interventional Phases: Phase2 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Choline — Choline 300mg tid or 500mg bid, p.o
  • Drug: anti-PD-1 antibody and chemotherapy — PD-1 antibody SHR1210 200mg q2w chemotherapy (whether and which should be given depends on the treatment regimen before enrollment)
  • Drug: Sodium Cromoglicate — Sodium Cromoglicate will be administered intranasally (nasal spray) (5 spray each nostril 4 times a day, 1 mg/spray)
  • Drug: Efavirenz — Efavirenz 600mg qd, p.o
  • Drug: SHR-A1811 — 4.8mg/kg q3w
  • Drug: SHR-A2102 — 6mg/kg q3w
  • Drug: SHR-1316 — 1200mg q3w
  • Drug: Mecapegfilgrastim — Mecapegfilgrastim, 6mg, d3, q3w, s.c.

Primary Outcomes

  • Objective Response Rate (ORR) (Baseline until disease progression or loss of clinical benefit, assessed up to 6 months)
  • Immune changes in peripheral blood (Baseline until disease progression or loss of clinical benefit, assessed up to 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2022-06-30
Completion: 2027-03-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fudan University
Principal Investigators:
  • Zhimin Shao, Professor (PRINCIPAL_INVESTIGATOR) - Fudan U
Contact Information
Study Contact:
Zhimin Shao, Professor
08664175590
zhimingshao@yahoo.com
Zhonghua Wang, Professor
08664175590
zhonghuawang95@hotmail.com
Zhonghua Wang, Professor
+8664175590
zhonghuawang95@hotmail.com
Fudan University Shanghai Cancer Center
Interventions
  • Drug: Choline — Choline 300mg tid or 500mg bid, p.o
  • Drug: anti-PD-1 antibody and chemotherapy — PD-1 antibody SHR1210 200mg q2w chemotherapy (whether and which should be given depends on the treatment regimen before enrollment)
  • Drug: Sodium Cromoglicate — Sodium Cromoglicate will be administered intranasally (nasal spray) (5 spray each nostril 4 times a day, 1 mg/spray)
  • Drug: Efavirenz — Efavirenz 600mg qd, p.o
  • Drug: SHR-A1811 — 4.8mg/kg q3w
Study Locations (1 sites)
Fudan University Shanghai Cancer Center, Shanghai, 200032 China
Eligibility Criteria
Inclusion Criteria: * ECOG Performance Status of 0, 1, or 2 * Metastatic or locally advanced, histologically documented TNBC (absence of HER2, ER, and PR expression) * Radiologic/objective evidence of recurrence or disease progression after immunotherapy(combined with targeted therapy or chemo ) for metastatic breast cancer(MBC) * Adequate hematologic and end-organ function, laboratory test results, obtained within 14 days prior to initiation of study treatment. * For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures as outlined for each specific treatment arm * Measurable disease according to Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1) * have the cognitive ability to understand the protocol and be willing to participate and to be followed up. Exclusion Criteria: * Symptomatic, untreated, or actively progressing CNS metastases * Active or history of autoimmune disease or immune deficiency * Significant cardiovascular disease * History of malignancy other than breast cancer within 5 years prior to screening, with the exception of those with a negligible risk of metastasis or death * Treatment with chemotherapy, radiotherapy,immunotherapy or surgery (outpatient clinic surgery excluded) within 3 weeks prior to initiation of study treatment. * Pregnancy or breastfeeding, or intention of becoming pregnant during the study * History of allergies to the drug components of this trial * History of eosinophilosis or mastocytosis * Patients who have been using oral steroid hormones for a long time will need to stop for 4 weeks if they have used them occasionally in the past * For the Mecapegfilgrastim group, patients had previously received PEG-rhG-CSF in combination with immunotherapy.
Conditions Acute Radiation Dermatitis
Phase NA
Enrollment 54
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Acute radiation dermatitis (ARD) is almost universally experienced by patients with cancer during or after radiation therapy. This condition potentially leads to detrimental clinical outcomes as it adversely affects adherence to prescribed subsequent management and further worsens quality of life. Nevertheless, there remains no consensus on the appropriate intervention for ARD. This pilot two parallel-group randomized trial aims to clinically assess the potential of bacterial cellulose-monolaurin hydrogel, compared to placebo cream, to prevent high-grade ARD among Filipinos with breast cancer up to four weeks after last radiotherapy session.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Triple

Interventions / Regimen

  • Other: Bacterial cellulose-monolaurin hydrogel — Hydrogel containing Komagataeibacter xylinus-derived bacterial cellulose, virgin coconut oil monolaurin, cucumber fragrance and distilled water
  • Other: Placebo cream — Cream containing distilled water, white petrolatum, steady alcohol, propylene glycol, sodium laurel sulphate, methylparaben and propylparaben

Primary Outcomes

  • Incidence of high grade acute radiation dermatitis (Baseline to Week 4 post-radiotherapy)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-09-01
Completion: 2028-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 54 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of the Philippines
Contact Information
Study Contact:
Aedrian A Abrilla, MD
+639363193980
aaabrilla@up.edu.ph
Claudine Yap-Silva, MD
cysilva@up.edu.ph
Claudine Yap-Silva, MD
cysilva@up.edu.ph
Philippine General Hospital
Interventions
  • Other: Bacterial cellulose-monolaurin hydrogel — Hydrogel containing Komagataeibacter xylinus-derived bacterial cellulose, virgin coconut oil monolaurin, cucumber fragrance and distilled water
  • Other: Placebo cream — Cream containing distilled water, white petrolatum, steady alcohol, propylene glycol, sodium laurel sulphate, methylparaben and propylparaben
Study Locations (1 sites)
Philippine General Hospital, Manila, 1000 Philippines
Eligibility Criteria
Inclusion Criteria: * Female sex at birth * Age at least 18 years at the time of invitation * Eastern Cooperative Oncology Group (ECOG) Performance Status score of either 0 or 1 * With histopathologic diagnosis of breast carcinoma * Already completed prescribed mastectomy and chemotherapy (adjuvant or neoadjuvant) interventions * Scheduled to receive hypo fractionated postmastectomy-postchemotherapy radiation therapy Exclusion Criteria: * Pregnant or lactating * With concurrent or previous history of any malignancy * With history of mediastinal or thoracic irradiation * With current bilateral synchronous breast carcinoma * With diagnosis of metastases from any form of breast cancer * With any skin lesion in the planned radiation field deemed deramtologically and/or radiotherapeutically relevant * With concomitant disease states deemed clinically significant (connective tissue diseases, infections, uncontrolled chronic disorders, renal failure, hepatic dysfunction, etc.) * With known history of hypersensitivities and/or reactions against any component of either experimental or comparator interventions * Inability to personally provide informed consent or to personally comply with skin care instructions
Conditions Coronary Artery Disease
Phase PHASE4
Enrollment 88
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Open-label, randomized, cross-over study conducted in a single center, applied to patients receiving a polypill with 100 mg of acetyl salicylic acid and different doses of ramipril and atorvastatin for indication of secondary prevention according to clinical practice, with objective of analyzing the level of systolic blood pressure and LDL-cholesterol in the same patient in 2 different periods: one under treatment of 3 months with the polypill and another of 3 months with the components separately.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Crossover Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Drug: Polypill of acetylsalicylic acid, ramipril and atorvastatin — Administration of acetylsalicylic acid, ramipril and atorvastatin in a polypill during 3 months more
  • Drug: Drugs taken separately: acetylsalicylic acid, ramipril and atorvastatin — Patients will be receiving during 3 months more the same components acetylsalicylic acid, ramipril and atorvastatin than with the polypill

Primary Outcomes

  • LDL-cholesterol (Months 2 and 3 vs. Months 5 and 6)
  • Systolic blood pressure (Months 2 and 3 vs. Months 5 and 6)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2022-10-14
Completion: 2026-04-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 88 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fundación EPIC
Principal Investigators:
  • Iñigo Lozano, MD, PHD (PRINCIPAL_INVESTIGATOR) - Hospital de Cabueñes, Gijon
Contact Information
Study Contact:
Iñigo Lozano Martinez-Luengas, MD, PHD
+34630901145
inigo.lozano@gmail.com
Iñigo Lozano, MD, PHD
+34630901145
inigo.lozano@gmail.com
Hospital Universitario de Cabueñes
Interventions
  • Drug: Polypill of acetylsalicylic acid, ramipril and atorvastatin — Administration of acetylsalicylic acid, ramipril and atorvastatin in a polypill during 3 months more
  • Drug: Drugs taken separately: acetylsalicylic acid, ramipril and atorvastatin — Patients will be receiving during 3 months more the same components acetylsalicylic acid, ramipril and atorvastatin than with the polypill
Study Locations (1 sites)
Hospital Universitario de Cabueñes, Gijón, Principality of Asturias 33203 Spain
Eligibility Criteria
Inclusion Criteria: Patients over 18 years of age. Patients under treatment with the Trinomia® polypill in any of its presentations for indication of secondary prevention and who can make the 6 visits necessary to complete the study. Patients who sign the Informed Consent. Exclusion Criteria: Patients who do not sign the informed consent. Patients with an inability to understand and comply with the protocol. Patients with contraindication to any component of the polypill. Patients who are already participating in another clinical trial. Patients with any condition that limits life expectancy to \<1 year. Patients with programmed coronary revascularization. Patients with coronary stent implantation in the last 12 months. Patients treated with any antithrombotic drug in addition to acetylsalicylic acid, that is, low molecular weight heparin, P2Y12 receptor inhibitors, or oral anticoagulants.
Conditions Breast Cancer
Phase Not Applicable
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Cell-based immune therapy using modified macrophages is a promising therapeutic approach in breast cancer. The objective of this cohort study is to collect tumor samples to develop patients' derived organoids to test the antitumor activity of newly developed CAR-macrophages. Other biological samples will be collected such as blood to analyze the host inflammatory status.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Antitumor activity of the CAR-macrophages against organoids from HER2 negative, HER2 low and HER2 positive breast cancers (24 months)
  • Antitumor activity of the CAR-macrophages compared to non-modified macrophages (24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2021-11-02
Completion: 2027-12-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Centre Oscar Lambret
Collaborators: Institut National de la Santé Et de la Recherche Médicale, France
Contact Information
Study Contact:
Nawale HAJJAJI, MD PhD
+33 320295910
n-hajjaji@o-lambret.fr
Nawale Hajjaji, MD, PhD
Oscar Lambret Center
Interventions
N/A
Study Locations (1 sites)
Oscar Lambret Center, Lille, 59000 France
Eligibility Criteria
Inclusion Criteria: * Male or female aged 18 years or more * Histologically confirmed breast cancer at any stage * Requiring surgery or tumor biopsy as standard of care * Any or no systemic treatment * Signed informaed consent * Health insurance coverage Exclusion Criteria: * Opposed to biospecimen collection

A Beta-only IL-2 ImmunoTherapY Study

NCT05086692
Recruiting
Conditions Advanced Solid Tumor, Unresectable Solid...
Phase PHASE1, PHASE2
Enrollment 115
Locations 27 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: MDNA11 — MDNA11 will be administered, IV on a once every 2 weeks (Q2W) dosing schedule. Provisional dose cohorts for monotherapy dose escalation doses ranging from 0.003 to 0.6 (mg/kg): until determining the monotherapy Recommended Dose for Expansion (mRDE).
  • Drug: Pembrolizumab (KEYTRUDA®) — MDNA11 will be administered in combination with pembrolizumab, IV. MDNA11 dose range to be evaluated in combination with pembrolizumab until determining the combination Recommended Dose for Expansion (cRDE).

Primary Outcomes

  • MDNA11 Recommended Dose for Expansion for monotherapy (mRDE) and Recommended Dose for Expansion for combination (cRDE) (24 months)
  • Incidence of Treatment Related Adverse Events (TRAEs) (24 months)
  • Incidence of Treatment Emergent Adverse Events (TEAEs) (24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2021-08-27
Completion: 2026-12-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 115 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Medicenna Therapeutics, Inc.
Collaborators: Merck Sharp & Dohme LLC
Principal Investigators:
  • Nina Merchant (STUDY_DIRECTOR) - Medicenna Therapeutics
  • Arash Yavari, MBBS (STUDY_CHAIR) - Medicenna Therapeutics
Contact Information
Study Contact:
Nina Merchant
604-340-3081
nmerchant@medicenna.com
Melissa Coello
267-476-2313
mcoello@medicenna.com
Interventions
  • Drug: MDNA11 — MDNA11 will be administered, IV on a once every 2 weeks (Q2W) dosing schedule. Provisional dose cohorts for monotherapy dose escalation doses ranging from 0.003 to 0.6 (mg/kg): until determining the monotherapy Recommended Dose for Expansion (mRDE).
  • Drug: Pembrolizumab (KEYTRUDA®) — MDNA11 will be administered in combination with pembrolizumab, IV. MDNA11 dose range to be evaluated in combination with pembrolizumab until determining the combination Recommended Dose for Expansion (cRDE).
Study Locations (27 sites)
Sharp Memorial Hospital, San Diego, California 92123 United States
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California 94158 United States
Providence Saint John's Health Center, Santa Monica, California 90404 United States
Boca Raton Regional Hospital, Boca Raton, Florida 33486 United States
Emory - Winship Cancer Institute, Atlanta, Georgia 30322 United States
Karmanos Cancer Institute, Detroit, Michigan 48201 United States
MD Anderson Cancer Center, Houston, Texas 77030 United States
Scientia Clinical Research, Randwick, New South Wales 2031 Australia
Macquarie University, Sydney, New South Wales 2109 Australia
University of the Sunshine Coast, Buderim, Queensland 4556 Australia
Eligibility Criteria
Key Inclusion Criteria: 1. Aged at least 18 years (inclusive at the time of informed consent). 2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1. 3. Must be able and willing to provide written informed consent prior to start of any study procedures and assessments and must be willing to comply with all study procedures. 4. Histologically or cytologically confirmed locally advanced or metastatic solid tumor (see tumor types listed under conditions) 5. Demonstrated adequate organ function 6. Measurable disease as per Response Evaluation Criteria in Solid Tumors, (RECIST v1.1) and documented by CT and/or MRI. 7. Life expectancy of ≥ 12 weeks. 8. Women of childbearing potential (WOCBP) must have a negative pregnancy test at screening and within 72 hours before the first dose of study drug(s). Women must not be breastfeeding. 9. Agree to use highly effective contraception methods. WOCBP must agree to use highly effective birth control. Key Exclusion Criteria: 1. Last administration of prior antitumor therapy: * Prior systemic anti-cancer therapy including investigational agents within 4 weeks (could consider shorter interval for kinase inhibitors or other short half-life drugs) prior to start of treatment. * Prior radiotherapy within 2 weeks prior to start of treatment or has had a history of radiation pneumonitis. A 1-week washout is required for palliative radiation (\<2 weeks of radiotherapy) to non-CNS disease. * Radiation therapy to the lung that is \> 30Gy within 6 months prior to start of treatment. * Currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to start of treatment. Concomitant participation in an observational study must be discussed on a case-by-case basis with the MM for approval. 2. Has known active CNS metastases and/or carcinomatous meningitis. Patients with previously treated brain metastases may participate provided they are radiologically stable, i.e., without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to start of treatment, subject to discussion with MM. 3. Active malignancy (other than the disease under treatment in the study) within the previous 3 years except for curable cancers. 4. Condition requiring long-term systemic treatment with either corticosteroids \> 10 mg daily prednisone equivalent or any other form of immunosuppressive therapy within 7 days prior to start of treatment. 5. Clinically significant active, known or suspected autoimmune disease, or diseases that can be exacerbated with immunotherapy. 6. Severe pulmonary, cardiac or other systemic disease. 7. Known hepatitis B or C virus infection. 8. Females who are pregnant or lactating or planning to become pregnant during the study. 9. Has had an allogeneic tissue/solid organ transplant. 10. Active infection requiring systemic therapy. 11. Any medical, emotional or psychiatric condition that interfere with the patient's ability to adhere to the protocol 12. Any other underlying medical conditions that, in the Investigator's opinion, will make the administration of study drug(s) unsafe or obscure the interpretation of toxicity determination or adverse events. 13. Known severe hypersensitivity to any component of study drug(s). 14. Inability to comply with study and follow up procedures as judged by the Investigator.
Conditions Type2 Diabetes, Complication of Bariatri...
Phase NA
Enrollment 248
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Diabetes mellitus (T2DM) is the most common complication of obesity patients. According to previous literature reports, weight loss and metabolic surgery are powerful means to treat obesity complicated with T2DM. Roux-en-Y gastric bypass (RYGB) is the standard operation recommended by the international society. One-anastomosis gastric bypass (OAGB) was recommended by IFSO(the International Federation for the Surgery of OBESITY AND METABOLIC DISORDERS ) in 2018. In this study, two kinds of metabolic surgery will be compared. At present, focusing on the above two operations, only two effective randomized controlled clinical studies have been carried out, among which one single-center clinical study has been followed up for 2 years, and the primary end point is weight loss; Another multicenter study, with a 2-year follow-up, showed that the primary end point was weight loss, and the secondary index was the effectiveness of two surgical methods in the treatment of T2DM.There is still a lack of evidence-based evidence for the effectiveness and safety of the two surgical methods in the treatment of T2DM. This study will make high-level evidence about the advantages and disadvantages of OAGB and RYGB in the treatment of T2DM. In this study, a number of centers with rich experience and clinical research experience in weight loss and metabolic surgery in Asia will be combined to complete the enrollment of 248 patients. Those who meet the standards will be randomly divided into two kinds of operations, and they will be followed up for 5 years on schedule. The rate of lost follow-up is controlled within 20%, and the data integrity is controlled within 95%. Taking the blood glucose remission rate of type 2 diabetes as the main observation index, the prospective verification shows that OAGB is clinically effective in treating obesity with type 2 diabetes compared with RYGB.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: The laparoscopic One-anastomosis gastric bypass will consist of: — gastrointestinal anastomosis: anterior colon and posterior stomach gastrointestinal anastomosis size: diameter \< 1.5cm, linear anastomosis length 2.5cm biliary and pancreatic branches 200cm, food branches 100cm exact relationship with mesangial defect
  • Procedure: The laparoscopic Roux-en-Y gastric bypass will consist of: — the laparoscopic Roux-en-Y gastric bypass gastric sac size \< 30ml gastrointestinal anastomosis: anterior colon and posterior stomach gastrointestinal anastomosis size: diameter \< 1.5cm, linear anastomosis length 2.5cm biliary and pancreatic branches 50cm, food branches 150cm exact relationship with mesangial defect

Primary Outcomes

  • One year after operation, the complete remission rate of type 2 diabetes mellitus [HbA1c < 6%, fasting plasma glucose < 5.6 mmol/L, no need to use any hypoglycemic drugs] (1 year after surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-02-01
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 248 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Beijing Friendship Hospital
Collaborators: Beijing Tiantan Hospital, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, The Third Xiangya Hospital of Central South University, The First Affiliated Hospital of Soochow University, The Third People's Hospital of Chengdu, Taipei Medical University Hospital
Principal Investigators:
  • Zhongtao Zhang, M.D.;Ph.D (PRINCIPAL_INVESTIGATOR) - Beijing Friendship Hospital
Contact Information
Study Contact:
Zhongtao Zhang, M.D.;Ph.D
+86-13801060364
zhangzht@ccmu.edu.cn
Mengyi Li, M.D
+86-15810993198
limengyi@ccmu.edu.cn
Zhongtao Zhang, M.D.;Ph.D
+86-13801060364
zhangzht@ccmu.edu.cn
Beijing Friendship Hospital
Interventions
  • Procedure: The laparoscopic One-anastomosis gastric bypass will consist of: — gastrointestinal anastomosis: anterior colon and posterior stomach gastrointestinal anastomosis size: diameter \< 1.5cm, linear anastomosis length 2.5cm biliary and pancreatic branches 200cm, food branches 100cm exact relationship with mesangial defect
  • Procedure: The laparoscopic Roux-en-Y gastric bypass will consist of: — the laparoscopic Roux-en-Y gastric bypass gastric sac size \< 30ml gastrointestinal anastomosis: anterior colon and posterior stomach gastrointestinal anastomosis size: diameter \< 1.5cm, linear anastomosis length 2.5cm biliary and pancreatic branches 50cm, food branches 150cm exact relationship with mesangial defect
Study Locations (1 sites)
Beijing Friendship Hospital, Beijing, Beijing Municipality 100050 China
Eligibility Criteria
Inclusion Criteria: * 21-65 years old, Male/Female, East Asian population * 50 kg/m2≥BMI≥27.5kg/m2 * Type 2 diabetes duration ≥6 months * HbA1c≥7.0% * Currently receiving one or more oral/injectable hypoglycemic drugs (insulin /glucagon-like peptide-1 receptor agonist) * Recommendation for OAGB/RYGB evaluated by a multidisciplinary team Exclusion Criteria: * Underwent gastrointestinal surgery (gastric/duodenal surgery or bariatric surgery) * Fasting C-peptide level lower than 1/2 normal minimum * Active gastrointestinal ulcer is present * Helicobacter pylori infection is present * A history of serious cardiovascular and cerebrovascular diseases (myocardial infarction, stroke, etc.) * A history of cirrhosis (Child-Pugh≥A) * A history of chronic kidney disease (eGFR )\< 60 ml/min / 1.73 m2) * Inflammatory bowel disease is present (ulcerative colitis, Crohn's disease) * Chronic anemia is present, Hgb for male \<100g/L, for female \<90g/L * A desire to conception during the study period * Uncontrolled mental and psychological disorders are present * Expected survival\<5 years of end-stage disease or previous/current malignant tumor * Participated in clinical studies/trials that have the conflict of interest with the study * Unable to understand, refuse to participate and sign the informed consent * Gallstones require cholecystectomy * Reflux esophagitis above grade A